Clinical Trial Detail

Contact

Missing content? – Request curation!

Request curation for specific Genes, Variants, or PubMed publications.

Have questions, comments, or suggestions? - Let us know!

Email us at : ckbsupport@jax.org

NCT ID NCT03473925
Title Efficacy and Safety Study of Navarixin (MK-7123) in Combination With Pembrolizumab (MK-3475) in Adults With Selected Advanced/Metastatic Solid Tumors (MK-7123-034)
Recruitment Completed
Gender both
Phase Phase II
Variant Requirements No
Sponsors Merck Sharp & Dohme Corp.
Indications
Therapies
Age Groups: senior | adult
Covered Countries USA | CAN | AUS

Facility Status City State Zip Country Details
Honor Health ( Site 0005) Scottsdale Arizona 85258 United States Details
Florida Cancer Specialists ( Site 0003) Sarasota Florida 34232 United States Details
University of Maryland ( Site 0008) Baltimore Maryland 21201 United States Details
Henry Ford Health System ( Site 0006) Detroit Michigan 48202 United States Details
Duke University Medical Center ( Site 0004) Durham North Carolina 27710 United States Details
Blacktown Hospital Western Sydney Local Health District ( Site 0024) Blacktown New South Wales 2148 Australia Details
Scientia Clinical Research ( Site 0021) Randwick New South Wales 2031 Australia Details
Peter MacCallum Cancer Centre ( Site 0023) Melbourne Victoria 3000 Australia Details
Princess Margaret Cancer Centre ( Site 0031) Toronto Ontario M5G 2M9 Canada Details
Jewish General Hospital ( Site 0032) Montreal Quebec H3T 1E2 Canada Details
Sourasky Medical Center ( Site 0012) Tel Aviv 6423906 Israel Details
Seoul National University Bundang Hospital ( Site 0043) Seongnam-si Gyeonggi-do 13620 Korea, Republic of Details
Seoul National University Hospital ( Site 0042) Seoul 03080 Korea, Republic of Details
Severance Hospital Yonsei University Health System ( Site 0041) Seoul 03722 Korea, Republic of Details
*Shaded cells indicate that there was no data available from clincialtrials.gov for the field